Ab&B fortifies for battle over China’s vaccine market
With proceeds from a Hong Kong IPO, the loss-making biotech is bidding for a piece of China’s fiercely competitive market for flu and human rabies vaccines Key Takeaways: The company’s…
Hengrui Pharma targets obesity drug launch after test success
The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials Key Takeaways: Participants receiving…
Fortune smiles again on WuXi AppTec with profit surge
The drug services giant has forecast a jump in revenue for the first half and a doubling of net profit, after U.S. policy concerns abated Key Takeaways: The projected results…
HBM notches up another mega deal but is the model sustainable?
The biotech has agreed to sell rights to one of its cancer drugs under development for up to $670 million, adding more fuel to its share price rebound this year…
Medtide launches IPO to bulk up its weight-loss business
The pharmaceutical services firm wants to expand production of peptides used in anti-obesity drugs, but it faces fierce competition and other business risks Key Takeaways: The global market for developing…
Alphamab stake sale could signal harder times ahead
The founder of the cancer drug developer has cashed out part of his holdings after the stock hit a price peak, raising questions about the firm’s earnings outlook Key Takeaways:…
CSPC Pharma teases big bucks deals after earnings miss
The Chinese drug giant revealed it was in talks with three parties to license its products for up to $5 billion in potential fees, a day after it delivered lackluster…
Recent Articles
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
- Everest Medicines drives growth with AI-powered mRNA pipeline
- Anti-toxin provider Jiangxi Institute joins biopharma IPO rush
- Biogene gets bruised in ‘Battle of the skincare belles’
- Switchbot taps market frenzy for robotic stocks
- Feihe’s sliding profits point to China dairy market past its sell-by date
- Smart driving equality: A battle for control of an emerging industry
